Abstract Details

Title Real-world switching patterns among US generic glatiramer acetate multiple sclerosis patients

Topic Multiple Sclerosis

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-099

Objective To characterize descriptively the demographics and switching patterns of patients taking FOGA

Background The first FDA-approved generic follow-on glatiramer acetate (FOGA) for multiple sclerosis (MS) in the US, Glatopa 20 mg/mL, was introduced in April 2015. Persistence data on FOGA are relevant to inform optimal clinical treatment decisions when different treatment choices exist, including Copaxone (branded glatiramer acetate [GA]) and FOGAs.

Design/Methods Adult MS patients with ≥1 pharmacy claim or written prescription for FOGA (Glatopa 20 mg/mL) between 01JUN2015 and 30SEPT2017 were analyzed from OM1, a US health claims database.

Results Patients with a FOGA claim (n=1,957) had a mean age of 51 years, median 1.35 years of follow-up and were 75% female. Of these patients, 46% had a prior fill for once-daily branded GA 20 mg/mL. Discontinuing initial treatment with FOGA was defined as either switch to another disease modifying therapy (DMT) or a gap in medication >60 days. Of the total, 82% (n=1,597) discontinued FOGA after a median of 30 days, while 18% (n=360) remained on FOGA. Of the discontinued patients (n=1,597), 56% (n=891) switched to ≥1 DMT and 38% (n=599) showed no evidence of starting another DMT. Of patients who discontinued, 17% (n=267) restarted FOGA at some time. Overall, 84% of the patients who switched to another DMT (n=748), initially switched to branded GA, with n=497 (56% of n=891) switching to branded GA 20 mg/mL. Of those patients who switched DMT more than once (n=280), 49% (n=137) switched at some point to FOGA.

Conclusions While the reasons are under investigation, the majority of FOGA-treated patients who discontinued did so within a relatively short time period. The majority who switched to another DMT, switched to branded GA. These findings highlight the importance of understanding discontinuation and DMT switching behaviors associated with new MS therapies.

Authors/Disclosures
Jessica K. Alexander, PhD (Jazz) PRESENTER	Jessica K. Alexander has received personal compensation for serving as an employee of Teva Pharmaceuticals. Jessica K. Alexander has received stock or an ownership interest from Teva Pharmaceuticals.
	No disclosure on file
Sigal Melamed-Gal	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��